Lectin chip for detecting carbohydrate chain markers based on blood serum and commonly based on protein in blood serum and saliva as well as kit and application of lectin chip

Abstract

The invention provides a lectin chip for detecting carbohydrate chain markers based on protein in blood serum or saliva as well as a kit and application of the lectin chip, relates to the lectin chip for detecting the carbohydrate chain markers in blood serum or saliva, and particularly relates to the lectin chip for detecting the carbohydrate chain markers based on protein in blood serum and saliva as well as a kit and application of the lectin chip. The invention aims at providing a non-injury lectin chip for detecting the carbohydrate chain markers by identifying protein in saliva or blood serum and a method thereof. The lectin chip for detecting the carbohydrate chain markers based on serum carbohydrate binding protein, provided by the invention, comprises a testing lectin probe set, wherein the testing lectin probe set at least comprises PTL-I, PNA, AAL, LTL, STL, BS-I, PTL-II, SBA, ACA, UEA-I, MAL-I and PHA-E+L. The lectin chip can be used for rapidly detecting a specific carbohydrate protein chain structure in blood serum and saliva samples, and rapidly judging the specific combination of carbohydrate chains in the samples, so as to determine whether corresponding people have hepatitis or not and determine whether people are ACHBLF patients or not.

Description

technical field [0001] The invention relates to a lectin chip for detecting sugar chain markers, in particular to a lectin chip for detecting sugar chain markers based on serum and jointly based on proteins in serum and saliva and an application thereof. Background technique [0002] Severe hepatitis B refers to massive degeneration and necrosis of liver cells, liver failure, loss of liver biosynthesis, transformation, and detoxification functions, accumulation of metabolites in the body, and serious disturbance of the internal environment. Encephalopathy, obvious bleeding, or secondary infection, cerebral edema, acute renal failure, etc. Therefore, clinically, it has the characteristics of severe disease, rapid development, and dangerous onset. If it is not actively treated, the prognosis will be extremely poor. The pathogenesis of severe hepatitis may be related to the host's hyperactive immune response and the effect of endotoxin. Its incidence accounts for about 1% of h...

AI Technical Summary

Problems solved by technology

[0009] At present, the research on glycosylation is mostly reported in other liver diseases (hepatitis B, cirrhosis, liver cancer). For example, the level of Gal-type double-antenna type N-glycan chain in serum of patients with liver fibrosis after hepatitis B virus (HBV) infection is significantly higher than that of healthy people Volunteers, at the same time, the levels of double-antennary and three-antennary N-glycan chains in serum decreased with the aggravation of liver fibrosis. 6) The level of N-glycan chains in Fucated biantennary type increased, while the level of N-glycan chains in triantennary type decreased, indicating that changes in the level of specific N-glycan chains in serum can be used to monitor the development of fibrosis, but in severe type B Not reported in hepatitis

Images